small molecule

OLUX E

CLOBETASOL PROPIONATE

Loss of exclusivityNovember 2028latest FDA-listed patent expiry
CompanyPHARMOBEDIENT CONSULTING LLC

Drug detail

Brand nameOLUX E
Active ingredientCLOBETASOL PROPIONATE
Strength0.05% **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Dosage formAEROSOL, FOAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalJanuary 2007
Marketing statusDISCN

Listed patents

PatentExpiresType
8460641November 2028product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

OLUX E patent cliff — loss of exclusivity November 2028 | CliffBio